April 24th 2024
Posters from the Academy of Managed Care Pharmacy annual meeting featured studies on atopic dermatitis.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
AD Case Study: Topical Steroids Are Not Cutting It
November 28th 2023Ted Lain, MD, MBA, moderated a discussion to share strategies to optimize treatment sequencing, reevaluate long-term management, understand barriers to novel therapies, promote prior authorization integration, and diversify treatment areas.
Case 2: Male, 58 Years Old with AD
November 8th 2023Dr Omar Noor delves into the complexities of boxed warnings tied to JAK inhibitors, contrasting their presence in systemic forms with the absence in the oral version of topical ruxolitinib, and discusses the potential impact on dialogues with both patients and fellow healthcare providers. He further underscores the pivotal role of long-standing safety data in building provider confidence in a treatment.
Case 1: Female, 28 Years Old, African American
November 8th 2023Omar Noor, MD, FAAD, discusses the critical role of patient education and transparent communication in the context of treating individuals with atopic dermatitis. He emphasizes the significance of cultivating trust in patient-provider relationships, explores the potential necessity of shifting the treatment paradigm, and addresses the implications of treatment interruptions or transitions in the long-term management of this condition, all while considering the crucial aspect of access to care.